Abstract. Robust multiple-fate morphogen gradients are essential for embryo development. Here, we analyze mathematically a model of morphogen gradient (such as Dpp in Drosophila wing imaginal disc) formation in the presence of non-receptors with both diffusion of free morphogens and the movement of morphogens bound to non-receptors. Under the assumption of rapid degradation of unbound morphogen, we introduce a method of functional boundary value problem and prove the existence, uniqueness and linear stability of a biologically acceptable steady-state solution. Next, we investigate the robustness of this steady-state solution with respect to significant changes in the morphogen synthesis rate. We prove that the model is able to produce robust biological morphogen gradients when production and degradation rates of morphogens are large enough and non-receptors are abundant. Our results provide mathematical and biological insight to a mechanism of achieving stable robust long distance morphogen gradients. Key elements of this mechanism are rapid turnover of morphogen to non-receptors of neighoring cells resulting in significant degradation and transport of non-receptor-morphogen complexes, the latter moving downstream through a "bucket brigade" process.
1. Introduction. At some stages of embryonic development, signaling protein molecules known as Morphogens (aka ligands) are synthesized at a localized site, some of them disperse from their production site, bind to cell receptors along the way, and result in different receptor occupancies at different cell locations. The spatial concentration gradient of morphogen-receptor complexes (aka signaling gradients) induces spatially graded differences in cell signaling. The differential cell signaling in turn gives rise to different gene expressions from which follow different stable cell fates and visual tissue patterns and organs during development.
In general, it is important for a developing biological organism to form appropriate morphogen gradients that appear at a proper time and proper place and are robust with respect to perturbations in system architecture, environmental changes, or signaling noise. As conflicting biochemical processes and strategies may be required to attain precision and robustness, the delineation of how both characteristics can be achieved in biological development remains a challenge in systems biology [19] . Different mechanisms and processes involved in the formation of different morphogen gradients are either known or have been proposed [2, 3, 7, 8, 9, 13, 14, 15, 16, 29, 30] . One process that remains indispensible is the transport of morphogens away from their localized source.
A number of models have been proposed for morphogen transport; most are based on diffusion of morphogen molecules and their interactions with signalling and non-signaling extracellular molecules [5, 7, 11, 12, 13, 16, 17, 18] . It has been argued that diffusion alone may not be a reliable mechanism as the resulting gradients are sensitive to substantial changes in system parameters, leading to a signaling gradient that is no longer biologically useful [19, 21, 24, 31] . Many additional mechanisms such as transcytosis, dynamin-mediated endocytosis, feedback control and regulations by membrane-associated non-receptors have been suggested for achieving robustness [4, 5, 7, 15, 23, 24] .
Regulations by non-signaling receptor (or non-receptor for short) such as heparan sulfate proteoglycans (HSPG) in morphogen movement are observed in many experiments [1, 2, 3, 6, 9, 10] , and the effects of the presence of non-receptors on the existence and characteristics of the steady-state signaling morphogen gradients have been studied in [20, 22, 23, 24] . From these studies, the desired robustness with respected to substantial perturbations of morphogen synthesis rate is seen to be achievable through two different mechanisms involving regulations of non-receptors:
Mechanism 1: Substantial (reversible) binding of slowly turned over morphogen molecules with membrane-bound non-receptors with the resulting non-signaling (morphogen) complexes degrading at a sufficiently rapid rate [24] . Mechanism 2: Fast binding of rapidly turned over free morphogen molecules with non-receptors so that the non-signaling complexes move downstream through a "bucket brigade" process [23] .
Mathematical analysis of the effectiveness of these two robustness mechanisms have been carried out in [23, 24] based on reaction-diffusion models with only one diffusion term in either free or non-signaling bound-morphogens. These one diffusion models however are biologically incomplete because it is possible to have both types of transport. Models with two diffusions have been developed and studied in [22, 26, 32] with the numerical simulations carried out in [22] suggesting that Mechanism 2 continues to ensure robustness if the free morphogen degradation is large enough.
In this paper, we analyze mathematically a model of morphogen gradient formation with both diffusion of free morphogens and the movement of non-signaling morphogen complexes through a "bucket brigade" process to establish a theory capable of predicting previous results from numerical simulations [22] . The model here (corresponding to the Dpp gradient in the wing imaginal disc) is unrelated to, and conceptually different from those of [26, 32] where the non-receptors are freely diffusing (Sog) molecules. We prove for our model the existence, uniqueness, and stability of the (quasi-)steady-state signaling gradient and thereby validating Mechanism 2 for tissue pattern formation. We also prove robustness of the steady state signaling gradient with respect to a significant increase in ligand synthesis rate under the assumption of low receptor and non-receptor occupancy and high free morphogen degradation rate compared with its diffusion rate.
2. Formulations.
Model equations.
We refer the mathematical model in [22, 23] , which was based on the formation of morphogen gradient in Drosophila wing imaginal discs regulated by the glypican members of heparan sulfate proteoglycans [3] . The [LN] . Distributions of various morphogen concentrations in the wing imaginal disc are assumed to be sufficiently uniform in two directions (except possibly for boundary layers) to change only along the antero-posterior axis. The anterior and posterior compartments are taken to be sufficiently symmetric so that we can focus on the posterior compartment that spans the range −d 0 ≤ X ≤ X max with a narrow region of ligand synthesis at −d 0 ≤ X ≤ 0. Both [L] and [LN] are allowed to diffuse; other main reactions include binding and unbinding of ligand to receptors and non-receptors, degradation of ligands, receptors and the ligand-receptor complexes. The total concentration of non-receptor binding sites is abundant and assumed to be a constant N 0 . Therefore, the resulting reaction-diffusion equations is (see [23] for an expanded discussion of the D LN term):
where X ∈ (−d 0 , X max ). The production rate of ligands is given in terms of the Heaviside unit step function H(z):
where v 0 is a constant ligand synthesis rate in the production region −d 0 ≤ X < 0. The boundary of the region is specified by X = X max . The receptor synthesis rate is assumed to depend only on [LR] and not on X and T explicitly. Assumed symmetry at the border X = −d 0 requires the no flux conditions: The edge X = X max is taken to be a sink for all diffusive elements so that
With V (X) discontinuous at X = 0, we stipulate the continuity of to have only a simple jump discontinuity at X = 0. Before the onset of ligand production (V (X) = 0), there is no ligand concentration of any kind so that
The receptors are expected to be in a steady-state prior to the onset of ligand production, so that
This implies
where R 0 is the concentration of unbound receptors at the steady-state prior to the onset of ligand production.
The conditions (1)- (9) define an initial-boundary value problem (IBVP) for morphogen gradient formation. The model in [23] corresponding to the special case with D L = 0. With D L = 0 herein, the corresponding mathematical problem becomes more difficult to analyze and requires a new approach.
Similar to [23] , we introduce the following non-dimensional quantities:
Here k(u) is the normalized receptor synthesis rate satisfying k(0) = 1. The normalized ligand production rate is given by
Here η is the (dimensionless) effective production rate which is important for our discussion below. Using the above non-dimensional variables, equations (1)- (4) become
with initial conditions
and boundary conditions ∂l ∂x x=0 = ∂w ∂x x=0 = l| x=1 = w| x=1 = 0, (t ≥ 0).
2.2. Steady-state behavior. In cell signaling and pattern formation, we are interested in the (quasi-)steady-state signaling gradient long after the onset of ligand production. The steady-state gradients satisfy (15)- (18) with all time partial derivatives set to zero. Withl(x),r(x),ū(x),w(x) denoting the steady-state solution for l(x, t), r(x, t), u(x, t) and w(x, t) of (15)- (20), respectively, we get the following two ODE forl andw
where the functionsū andr depend onl through
The boundary conditions for (21) arē
Hereafter a prime, , indicates differentiation with respect to x. We are only interested in solutions of (21)- (23) that are biologically realistic (or "biological gradient" for brevity). The concentration of the corresponding bound morphogen-non-receptor gradient is restricted by the total number of binding sites of non-receptors, i.e., 0 ≤ [LN] ≤ N 0 . Also, the (realistic) biological gradients must be non-negative. In terms of non-dimensional variables, biological gradients should satisfy
(24) We note that it is possible to havel(x) > 1 when x is small because of a high ligand synthesis rate. This motivates the following definition for a biologically acceptable gradient.
Definition 2.1. The four functions {w(x),l(x),r(x),ū(x)} are said to be biologically acceptable gradients if the functions satisfy equations (22) and inequalities (24) for any 0 ≤ x ≤ 1 and ifw(x) andl(x) satisfy the BVP (21)- (23).
We always assume a non-positive feedback of receptor production, which is characterized by the function k(u) as follows.
Definition 2.2. The function k(u) is said to be a non-positive feedback if
In the following discussion, we extend the domain of k(u) to all real number by setting k(u) = k(0) for all u < 0.
In the results section below, we study the biologically acceptable gradients of (21)- (23) . In [23] , we investigated the well-posedness of the BVP for the special case of θ l = 0 through the methods of upper and lower solutions and nonlinear eigenvalue problem previously developed [25, 27] . However, when θ l = 0, these methods are not applicable directly. To establish well-posedness, we introduce new methods based on functional differential equations which are also different from those employed in [26, 32] for problems with two diffusion elements.
Results.
3.1. Existence and uniqueness of the steady-state solution. This section proves the the following theorem on the existence and uniqueness of the steadystate solution.
Theorem 3.1. Consider the BVP (21)- (23), if k(u) is a non-positive feedback, and
there exists a unique combination of biologically acceptable gradients {w,l,ū,r}.
Before proving Theorem 3.1, we observe the following gradient properties:
is a non-positive feedback and µ > 0. Then for anȳ
for the unique positive solutionū =ū(l),r =r(l) of (22) Proof. All conclusions in this lemma are direct consequences of (22) .
From Lemma 3.2, the BVP (21)- (23) can be rewritten in the following form:
To prove Theorem 3.1, we only need to show that the BVP (27) has a unique solution satisfying 0 <w(x) < 1 andl(x) > 0 for 0 ≤ x ≤ 1. This is done by treating two particular cases of the uncoupled form of (27): 1. For anyw(x) with 0 ≤w(x) ≤ 1, prove that the BVP
has a unique solutionl(x) > 0. In particular, the solution is written as
wherel 0 (x) is the solution of (28) whenw ≡ 0, and Lw(x), as defined by (29), is a functional ofw satisfying
2. Upon rewriting the BVP
as a functional boundary value problem
prove that (32) has a unique solution.
The proofs of these two propositions above are given below in Lemmas 3.3-3.5. For the proofs, we hereafter denote H 0 (I, R) the space of continuous real-valued functions defined on
) and H 0 (I, C) are defined similarly.
Lemma 3.3. For anyw ∈ H 0 (I, I), the equation
has a unique positive solution. Furthermore, the solution satisfies
Letl 0 (x) be the solution of (33) withw(x) ≡ 0, then
and
Proof. For anyw ∈ H 0 (I, I), it is easy to see thatl U (x) ≡ η/ε+1 andl L (x) ≡ 0 are respectively upper and lower solutions of (33). From Lemma A.1 in the Appendix, there exits a unique solution of the BVP (33) such that 0 ≤l(x) ≤ η/ε+1. Similarly, we have 0 <l 0 (x) < η/ε.
Again, Lemma A.1 yields a unique solution of (37) that satisfies
and the Lemma is proved.
From Lemma 3.3, we define an operator L :
withl(x) andl 0 (x) as in Lemma 3.3, then for anyw ∈ H 0 (I, I)
Lemma 3.4. Let L w as defined in (38), then for anyw 1 ,w 2 ∈ H 0 (I, I),
Proof. Write ϕ(x) = Lw 1 (x) − Lw 2 (x), and
Since ∂ū/∂l > 0, we have q(x) > 0. Now, applying Lemma A.3, we obtain
Lemma 3.5. Consider the functional differential equation
where Lw is defined as previous so that
then (42) has a unique solution in H 0 (I, I).
Proof. Letw 0 (x) to be the solution of
Lemma A.1 yields that (46) has a unique solution and 0
From Lemma A.3, there is a Green function G(x, s) that is positive for any 0 ≤ x, s ≤ 1, and (47) is equivalent to the following functional integral equation
Thus, the boundary value problem (42) is equivalent to the following functional integral equationw = Tw (49) where
Hence, it is sufficient to show that the operator T maps H 0 (I, I) into itself and is a contraction map.
First, it is easy to see Tw ∈ H 0 (I, R) and Tw(x) ≥ 0 (0 ≤ x ≤ 1) for anȳ w ∈ H 0 (I, I). Second, we have G(x, s) > 0 from Lemma A.3. Note (43), therefore
The right hand side of (50), denoted asw U (x), satisfies the equation
which yieldsw
by (45). It follows that Tw(x) ≤ 1, (0 ≤ x ≤ 1) and hence Tw maps H 0 (I, I) into itself.
Next, we show that T is a contraction map. Letw 1 ,w 2 ∈ H 0 (I, I), then
and therefore T is a contraction (since
As the map T is a contraction map from H 0 (I, I) into itself, it has a unique fixed point, which is the solution of (42). The Lemma is proved.
3.2.
Linear stability of the steady-state gradient. For the biological (quasi-) steady state behavior to be relevant for tissue patterning, it should be stable. We show here that this is in fact the case, at least by a linear stability analysis. For linear stability, we consider a small perturbation from the steady-state in the form
wherel,r,ū,w are the steady-state solutions and where the time-independent portion of the perturbations,l,r,ũ andw, are negligibly small. After linearlization, we have the following eigenvalue problem
−ξr = δ r (µ(αũ −rl −lr) + (k (ū)ũ −r)) (54)
with boundary conditionsl
We solve (54)-(55) forr,ũ to get
Hence, the perturbationsl,w satisfy the following nonlinear eigenvalue problem
where
The following theorem establishes the local stability of the steady-state solution.
Theorem 3.6. If k(u) is a non-positive feedback, and
then all eigenvalues of the nonlinear eigenvalue problem (57) have positive real parts and therefore the biologically acceptable gradient combination {w(x),ū(x),l(x),r(x)} is asymptotically stable.
Proof. We assume (ξ) ≤ 0 and prove a contradiction by showing that for any ξ such that (ξ) ≤ 0, the BVP problem (57) has only a zero solution. First, consider the equation
When (ξ) ≤ 0, we have
Thus, Lemma A.2 implies that for anyw ∈ H 0 (I, C), (59) has a unique solution, which is given by an operator G ξ below:
Here G(x, s) is the corresponding Green function and satisfies
from Lemma A.3. The operator G ξ mapsw ∈ H 0 (I, C) to the unique solutionl(x) of (59). Moreover, G ξ is linear, and from Lemma A.2 and (34), (60),
Now, the eigenvalue problem (57) reduces to a functional eigenvalue equation
It is easy to see (B ξ (x)) > λ 2 − (ξ) > 0. Thus Lemma A.3 yields a Green function K ξ (x, s) such that (62) is equivalent to the following functional integral equatioñ
Here F ξ is an operator maps H 0 (I, C) into itself. From Lemma A.3, we have
For any w 1 , w 2 ∈ H 0 (I, C),
Thus, (58) implies F ξ (w 1 ) − F ξ (w 2 ) < w 1 − w 2 . Hence, the operator F ξ is a contraction map and (62) has only the zero solution.
We have proved that if (ξ) ≤ 0, (57) has only the zero solution. Therefore, all eigenvalues of problem (57) must have positive real part and the Theorem is proved.
3.3.
Robustness of the steady-state solution. We have established the existence, uniqueness and stability of the biologically acceptable gradients. In this section, we consider the robustness of the corresponding signaling gradient when the ligand production rate is changed.
We focus here on the dependence of the signaling gradient on the ligand production rate characterized by the dimensionless constant η. To this end, denote the dimensionless signaling concentration byū(x; η). As in [21, 22, 23, 24] , we characterize the robustness of the signaling gradient with respect to changes in ligand production rate by a robustness index R(η, η ), defined as the relative change of the signaling gradient when the parameter η is changed to η R(η, η ) = 1 ∆η/η
Evidently, the smaller the value of R, the more robust is the signaling gradient. We adopt R < 0.2 for acceptable robustness as in [24] . In the definition (64), the explicit solutionū(x; η) is not known, and therefore not easy to calculate the robustness index. Here, we first perform analysis for the extreme case of ε 1 and θ l 1 to find a sufficient condition to have good robustness, and then examine more general cases by numerical simulations.
3.3.1. Approximation solution when ε 1 and θ l 1. First, we obtain an approximate solution when ε 1 and θ l 1 by the method of asymptotic expansions. For 0 < ε 1, a regular perturbation solution in ε ofw(x; ε, θ l ) andl(x; ε, θ l ) in (27) is appropriate. For the leading term solution, denoted byw 0 (x; θ l ) andl 0 (x; θ l ), the boundary value problem (22) decouples to result in two linear problems:
Note that the boundary value problem (66) is a direct consequence of the relevant equations in (27) 
Since the order of the differential equation (65) forw 0 is the same as that of (27), the solution (67)- (69) is in fact the leading term approximation (in ε) forw(x; ε, θ l ) (without any supplementary boundary layer component, at least not to this order of approximation). Havingw 0 (x; θ l ), the boundary value problem (66) forl 0 (x; θ l ) becomes
This simple linear problem may be solved by the method of variation of parameters. With 0 < θ l 1, we omit terms of order θ l (and ε) to get the approximate solution
(70) Correspondingly, the leading term solution for the signaling gradient is given implicitly bȳ
and the receptor gradient is given bȳ
3.3.2. Robustness with ε 1 and θ l 1. Now, we apply the above approximation to study the robustness when ε 1 and θ l 1. In this case, the robustness index R is approximated by
The following Theorem established an upper bound of the robustness index R 0 when the ligand production rate is increased (η > η). Theorem 3.7. Assume that η > η and k(u) is a non-positive feedback, the robustness defined by (73) satisfies
where A(η), B(η) are bounded for all η > 0. In particular, we have R 0 (η, η ) = O(η −1/2 ) (η > η) when η is sufficiently large.
Proof. First, we have
for some η ≤η(x) ≤ η and therewith
It is readily shown from (70) that
and from (71), we obtain
Thus, we have
Now, from (75), (76) and (70), we have
It is straightforward to obtain from (68)
Thus,
Next, we show that B(η) < ∞ for all η > 0. First, we see from (68) that there exist
thenl0(x; η) > w1(x) + ηh(x) for any η > η1, and therefore
Thus, we only need to show that B1(η) < ∞ for all η > 0.
It is straightforward to obtain from B1(η) above
which is negative when η is large enough. Therefore, we conclude that B1(η) < ∞. The Theorem has been proved.
From Theorem 3.7, the system is robust provide that the ligand synthesis rate is high. This theoretical result is confirmed by numerical simulations in Fig.1a (see [22] for simulations of a two-dimensional model).
3.3.3. Robustness for general cases. From the above analysis, when both ε and θ l are small and η is large, the system has good robustness. For general cases when either ε or θ is not small, analytic calculation of the robustness R is difficult. We perform numerical simulation with results given at Fig. 1b , which shows a contour plot of the threshold η as a function of (ε, θ l ) so that R = 0.2. From Fig. 1b , the threshold η increases quickly with ε and θ l . Thus, higher ligand synthesis rate is required to achieve good robustness for larger values of ε and θ l . 4. Discussion. In this paper, we study a mathematical model for signaling morphogen gradient formation in the presence of cell membrane-associated non-receptors and a non-positive feedback for signaling receptor production (such as Tkv for Dpp in Drosophila wing imaginal disc). We proved that when
the system has a unique steady-state solution, and the solution is linearly stable for all realistic range of parameter values. The steady state BVP is therefore well-posed.
the gradient is shown analytically to be robust with respect to changes in ligand production rate. Numerical simulations confirm this conclusion and show similar robustness for the general case. Biological significances of the conditions (77) and (78) can be understood in the following way by considering the concentration of extracellular ligands in the production region. In that region, when the ligand production rate is very high and the concentration of total non-receptors (N 0 ) is large compare to that of receptors (R 0 ), the effect of receptors is negligible because most ligands bind to non-receptors. We further neglect the diffusion because ligands are synthesis uniformly in this region. Therefore, the system includes only ligand production, degradation, and reversible binding with non-receptors: showing that η is the ratio of bound to free non-receptor concentration in the ligand production region.
The condition (77) is satisfied when ε is small enough, i.e., most of the free ligands are removed by degradation. A sufficiently large δ L also yields a small value of θ l . The condition η 1 is satisfied when the ligand synthesis rate is large (so that the ligand concentration is high at the production region) and non-receptors are in a state of high occupancy. Thus, the conditions (77) and (78) are satisfied with rapid synthesis and degradation of ligands.
From these theoretical results, we infer the following process for the formation of stable signaling biological gradients that are robust with respect to significant changes in ligand synthesis rate. A high ligand synthesis rate saturates the receptors and much of the non-receptors in the ligand production region where the signaling does not contribute to development and tissue patterning. Though excess ligand molecules are mostly removed by degradation with some transported downstream by normal diffusion (to bind with receptor and contribute to signaling gradient), those bound to non-receptors move along the "bridge" of cell bound non-receptors. These ligands then disassociate from the non-receptors, and are removed either by degradation or by binding with receptors to form signaling complex to regulate the expression of downstream genes. In this way, a signaling gradient is determined mainly by the amount of non-receptors available and is robust with respect to a perturbation in the ligand production rate as long as sufficient non-receptors are available for the task of bucket brigade transport. These observations are consistent with what has been observed in the case of Dpp gradient in Drosophila wing imaginal disc [3, 28] , in which cell membrane bound non-receptors are important in the formation of morphogen gradient and tissue development. 
Proof. It is easy to verify that y L (x) ≡ b 1 and y U (x) ≡ b 2 are lower and upper solutions of (80), respectively. Thus (80) has at least one solution that satisfies (82) according to the method of upper and lower solution [27] . Assume that there are two solutions y 1 (x) and y 2 (x). Let q(x) = f (x, y 1 (x)) − f (x, y 2 (x)) y 1 (x) − y 2 (x) , G(x, s)ds = r(x)e iϕ(x) , r(x), ϕ(x) ∈ H 0 (I, R).
It is a lengthy but straightforward calculation to show that r(x) and ϕ(x) satisfy two coupled differential equations one of which is r − ( (a(x)) + ϕ 2 (x))r − cos ϕ(x) = 0, r (0) = r(1) = 0.
Since ϕ ,
and (86) is proved. When a(x) ∈ H 0 (I, R), the relevant maximum principle requires that both φ 1 (x) and φ 2 (x) are positive with φ 1 (x) ≤ 0 ≤ φ 2 (x), and thus G(x, s) > 0.
